The company in-licensed a novel circulating tumor RNA (ctRNA) biomarker assay from Cirna Diagnostics in March 2026 to aid early diagnosis and surveillance of hepatocellular carcinoma (HCC). In April 2026, the company closed a private placement offering for $700,000 at $0.04 per share to accredited investors. Recent leadership transitions include CEO Dr. Kaouthar Lbiati's resignation in March 2026, with Gary Stetz appointed as interim CEO, and employment agreements signed with Vincent LoPriore (Executive Chairman) and Gary Stetz (Chief Executive Officer) in May 2026.
Cyborg Score Rationale
Hepion is a cash-constrained clinical-stage diagnostic company trading on OTC markets at severely depressed valuations (~$0.05 per share as of June 2026). The company is attempting a strategic pivot toward diagnostics with in-licensed biomarker assets, but faces execution risk with minimal employee base and recent leadership instability. Near-term viability depends on successful CLIA partnerships and commercialization traction for its methylated DNA and ctRNA assays.
Top Insights
Strategic shift from drug development (Rencofilstat/NASH) to diagnostics represents a capital-efficient pivot toward near-term commercialization of acquired biomarker platforms.
Dual biomarker portfolio (mSEPT9 methylated DNA + ctRNA assay) addresses both HCC-specific and broader solid tumor detection, potentially widening addressable market.
Recent funding round ($700K in April 2026) is minimal for a clinical-stage biotech, indicating severe capital constraints and likely dependence on partnerships for clinical validation and commercialization.
Leadership continuity challenges (interim CEO appointment in March 2026, immediate predecessor's resignation) may create execution risk on commercialization timelines.
Named Competitors
Guardant Health — Oncology liquid biopsy and cell-free DNA testing
Exact Sciences — Multi-cancer screening and precision diagnostics
mSEPT9 Platform — Methylated DNA biomarker diagnostics (HCC and other cancers)
Recent Developments
(March 2026) In-licensed ctRNA biomarker assay from Cirna Diagnostics for HCC early diagnosis and surveillance
(March 2026) CEO Dr. Kaouthar Lbiati resigned for personal reasons; Gary Stetz appointed interim CEO
(April 2026) Closed $700K private placement offering at $0.04 per share to accredited investors
(May 2026) Signed employment agreements with Executive Chairman Vincent LoPriore and CEO Gary Stetz
(June 2025) Successfully transitioned to OTCQB from previous listing status
Open the full interactive Hepion Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.